<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; innovative</title>
	<atom:link href="http://www.tapanray.in/tag/innovative/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Accelerating Footfalls In Less Charted Pharma Marketing Frontiers</title>
		<link>http://www.tapanray.in/accelerating-footfalls-in-less-charted-pharma-marketing-frontiers/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=accelerating-footfalls-in-less-charted-pharma-marketing-frontiers</link>
		<comments>http://www.tapanray.in/accelerating-footfalls-in-less-charted-pharma-marketing-frontiers/#comments</comments>
		<pubDate>Mon, 27 Mar 2023 00:00:44 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Collaborative]]></category>
		<category><![CDATA[conferences]]></category>
		<category><![CDATA[continualtion]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[footfalls]]></category>
		<category><![CDATA[frontiers]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[innovative]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Media]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[post]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Social]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Telehealth]]></category>
		<category><![CDATA[telemedicine]]></category>
		<category><![CDATA[virtual]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10755</guid>
		<description><![CDATA[Having experienced unprecedented disruptions, especially in the pharmaceutical and biopharmaceutical business, many global and local drug majors, are rethinking their marketing strategies. These have, no doubt, been prompted by the challenges of change, which are sometimes stark, but more often than &#8230; <a href="http://www.tapanray.in/accelerating-footfalls-in-less-charted-pharma-marketing-frontiers/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/accelerating-footfalls-in-less-charted-pharma-marketing-frontiers/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Focus On All 3 Areas of Innovation For Affordable Access To Innovative Drugs</title>
		<link>http://www.tapanray.in/focus-on-all-3-areas-of-innovation-for-affordable-access-to-innovative-drugs/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=focus-on-all-3-areas-of-innovation-for-affordable-access-to-innovative-drugs</link>
		<comments>http://www.tapanray.in/focus-on-all-3-areas-of-innovation-for-affordable-access-to-innovative-drugs/#comments</comments>
		<pubDate>Mon, 29 Nov 2021 00:00:53 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[ace]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[changing]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[differential]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[focus]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[innovative]]></category>
		<category><![CDATA[Issues]]></category>
		<category><![CDATA[Models]]></category>
		<category><![CDATA[outcomesbusiness]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[problem]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[solution]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[three areas]]></category>
		<category><![CDATA[tiered]]></category>
		<category><![CDATA[win-win]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10615</guid>
		<description><![CDATA[Medical treatment has made astonishing advances over the years. But the packaging and delivery of that treatment are often inefficient, ineffective, and consumer unfriendly. This was articulated in an article on innovation in healthcare, published in the Harvard Business Review, way &#8230; <a href="http://www.tapanray.in/focus-on-all-3-areas-of-innovation-for-affordable-access-to-innovative-drugs/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/focus-on-all-3-areas-of-innovation-for-affordable-access-to-innovative-drugs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Focus More To Create Patient-Perceived Value of Brand Outcomes</title>
		<link>http://www.tapanray.in/focus-more-to-create-patient-perceived-value-of-brand-outcomes/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=focus-more-to-create-patient-perceived-value-of-brand-outcomes</link>
		<comments>http://www.tapanray.in/focus-more-to-create-patient-perceived-value-of-brand-outcomes/#comments</comments>
		<pubDate>Mon, 01 Nov 2021 00:00:27 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2021]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[age]]></category>
		<category><![CDATA[brand outcomes]]></category>
		<category><![CDATA[changes]]></category>
		<category><![CDATA[channels]]></category>
		<category><![CDATA[Complex]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[create]]></category>
		<category><![CDATA[criticality]]></category>
		<category><![CDATA[deliver]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[group]]></category>
		<category><![CDATA[Index]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovative]]></category>
		<category><![CDATA[Media]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[older]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[perceived]]></category>
		<category><![CDATA[platforms]]></category>
		<category><![CDATA[process]]></category>
		<category><![CDATA[products]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[services]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[value]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10603</guid>
		<description><![CDATA[Healthcare providers, including many drug companies aim to create a beneficial effect on patients with their respective products and services. However, and more importantly, these benefits need to be such that recipients are able to sense, feel, and perceive as &#8230; <a href="http://www.tapanray.in/focus-more-to-create-patient-perceived-value-of-brand-outcomes/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/focus-more-to-create-patient-perceived-value-of-brand-outcomes/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Focus On Core Competencies &#8211; Regardless of Generic Or Innovative Drug Business</title>
		<link>http://www.tapanray.in/focus-on-core-competencies-regardless-of-generic-or-innovative-drug-business/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=focus-on-core-competencies-regardless-of-generic-or-innovative-drug-business</link>
		<comments>http://www.tapanray.in/focus-on-core-competencies-regardless-of-generic-or-innovative-drug-business/#comments</comments>
		<pubDate>Mon, 22 Feb 2021 00:00:23 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[antibiotics]]></category>
		<category><![CDATA[brands]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[Carving-out]]></category>
		<category><![CDATA[cephalosporin]]></category>
		<category><![CDATA[cephalosporins]]></category>
		<category><![CDATA[competencies]]></category>
		<category><![CDATA[core]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[focus]]></category>
		<category><![CDATA[Fortum]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovative]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[normal]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[Old]]></category>
		<category><![CDATA[perspective]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[regardless]]></category>
		<category><![CDATA[Relevance]]></category>
		<category><![CDATA[Sandoz]]></category>
		<category><![CDATA[shifting]]></category>
		<category><![CDATA[Spin-offs]]></category>
		<category><![CDATA[Splitting-off]]></category>
		<category><![CDATA[Strategic]]></category>
		<category><![CDATA[strength]]></category>
		<category><![CDATA[success]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Zinacef]]></category>
		<category><![CDATA[Zinnat]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10421</guid>
		<description><![CDATA[On February 11, 2021, by two different Press Releases, two global pharma majors – GSK and Novartis simultaneously made interesting announcements. Both were related to three generic cephalosporin antibiotics. GSK revealed, ‘it has reached an agreement with Sandoz &#8211; a &#8230; <a href="http://www.tapanray.in/focus-on-core-competencies-regardless-of-generic-or-innovative-drug-business/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/focus-on-core-competencies-regardless-of-generic-or-innovative-drug-business/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Time For Predictive Rather Than Reactive Pharma Strategy</title>
		<link>http://www.tapanray.in/time-for-predictive-rather-than-reactive-pharma-strategy/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=time-for-predictive-rather-than-reactive-pharma-strategy</link>
		<comments>http://www.tapanray.in/time-for-predictive-rather-than-reactive-pharma-strategy/#comments</comments>
		<pubDate>Mon, 15 Jun 2020 00:00:38 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Approach]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[Change]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[Digitalization]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[first in class]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[innovative]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[me-too]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[mindset]]></category>
		<category><![CDATA[molecule]]></category>
		<category><![CDATA[pathway]]></category>
		<category><![CDATA[predictive]]></category>
		<category><![CDATA[proactive]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reactive]]></category>
		<category><![CDATA[safe]]></category>
		<category><![CDATA[sailing]]></category>
		<category><![CDATA[sales]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[supply-chain]]></category>
		<category><![CDATA[system]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[traditional]]></category>
		<category><![CDATA[value-based]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10126</guid>
		<description><![CDATA[Traditionally, pharmaceutical industry, across the world, is mostly reactive &#8211; rather than proactive or predictive in its strategic approach &#8211; spanning across all its business domains. A large number of pharma players &#8211; both innovators and generic drug makers, formulate &#8230; <a href="http://www.tapanray.in/time-for-predictive-rather-than-reactive-pharma-strategy/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/time-for-predictive-rather-than-reactive-pharma-strategy/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Restart Pharma Demand Generation Activities With Actionable Insight</title>
		<link>http://www.tapanray.in/restart-pharma-demand-generation-activities-with-actionable-insight/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=restart-pharma-demand-generation-activities-with-actionable-insight</link>
		<comments>http://www.tapanray.in/restart-pharma-demand-generation-activities-with-actionable-insight/#comments</comments>
		<pubDate>Mon, 01 Jun 2020 00:00:34 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Actionable]]></category>
		<category><![CDATA[activity]]></category>
		<category><![CDATA[bedrock]]></category>
		<category><![CDATA[changes]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[demand]]></category>
		<category><![CDATA[distancing]]></category>
		<category><![CDATA[Generation]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Information]]></category>
		<category><![CDATA[innovative]]></category>
		<category><![CDATA[Insishr]]></category>
		<category><![CDATA[new normal]]></category>
		<category><![CDATA[pathway]]></category>
		<category><![CDATA[prescription]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[restart]]></category>
		<category><![CDATA[Social]]></category>
		<category><![CDATA[Social-distancing]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10107</guid>
		<description><![CDATA[As the ‘Lockdown. 04’ in India passes by, a time comes to press the restart button of all business activities in the country, in a calibrated manner, though, keeping in mind, the Covid-19 cases is yet to find its peak &#8230; <a href="http://www.tapanray.in/restart-pharma-demand-generation-activities-with-actionable-insight/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/restart-pharma-demand-generation-activities-with-actionable-insight/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>What Pays More: Creating ‘Innovative ‘Customer Experience’ Or ‘Innovative Drugs’?</title>
		<link>http://www.tapanray.in/what-pays-more-creating-innovative-customer-experience-or-innovative-drugs/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=what-pays-more-creating-innovative-customer-experience-or-innovative-drugs</link>
		<comments>http://www.tapanray.in/what-pays-more-creating-innovative-customer-experience-or-innovative-drugs/#comments</comments>
		<pubDate>Mon, 13 Jan 2020 00:00:34 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[branded]]></category>
		<category><![CDATA[brands]]></category>
		<category><![CDATA[business corporate]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[Consumerism]]></category>
		<category><![CDATA[Creating]]></category>
		<category><![CDATA[customer]]></category>
		<category><![CDATA[dimension]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[end-to-end]]></category>
		<category><![CDATA[equation]]></category>
		<category><![CDATA[expectations]]></category>
		<category><![CDATA[experience]]></category>
		<category><![CDATA[Failure]]></category>
		<category><![CDATA[financial]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[innovative]]></category>
		<category><![CDATA[life-cycle]]></category>
		<category><![CDATA[loyal]]></category>
		<category><![CDATA[loyalty]]></category>
		<category><![CDATA[marketers]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[more]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[pays]]></category>
		<category><![CDATA[performance]]></category>
		<category><![CDATA[pressure]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[prodrugs]]></category>
		<category><![CDATA[Promotion]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[traditional]]></category>
		<category><![CDATA[unique]]></category>
		<category><![CDATA[word-of-mouth]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9851</guid>
		<description><![CDATA[More innovative a drug is, the better is its business success rate. This was the general perception of around 92 percent pharma professionals in the past three years. Whereas the fact is: ‘Having the best product doesn’t guarantee sales anymore’. &#8230; <a href="http://www.tapanray.in/what-pays-more-creating-innovative-customer-experience-or-innovative-drugs/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/what-pays-more-creating-innovative-customer-experience-or-innovative-drugs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The Challenge of Holistic Value Creation With Pharma M&amp;A</title>
		<link>http://www.tapanray.in/the-challenge-of-holistic-value-creation-with-pharma-ma/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-challenge-of-holistic-value-creation-with-pharma-ma</link>
		<comments>http://www.tapanray.in/the-challenge-of-holistic-value-creation-with-pharma-ma/#comments</comments>
		<pubDate>Mon, 19 Aug 2019 00:00:58 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[acquisition]]></category>
		<category><![CDATA[avant-garde]]></category>
		<category><![CDATA[Broader]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[creation]]></category>
		<category><![CDATA[cycle]]></category>
		<category><![CDATA[Disruptive]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[experience]]></category>
		<category><![CDATA[greater]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovative]]></category>
		<category><![CDATA[launches]]></category>
		<category><![CDATA[M&A]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[merger]]></category>
		<category><![CDATA[NCE]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[NME]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[possibilities]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[redefining]]></category>
		<category><![CDATA[takeovers]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[unique]]></category>
		<category><![CDATA[value]]></category>
		<category><![CDATA[value-creation]]></category>
		<category><![CDATA[virtuous]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9675</guid>
		<description><![CDATA[Two mega deals, right at the dawn of 2019 gave a flying start to Merger &#38; Acquisition (M&#38;A) activities, in search of inorganic growth, by some large pharma companies. The two biggest ones are Bristol-Myers Squibb’s (BMS) USD 74 billion buyout of &#8230; <a href="http://www.tapanray.in/the-challenge-of-holistic-value-creation-with-pharma-ma/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-challenge-of-holistic-value-creation-with-pharma-ma/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Innovative ‘Medicines Too Damn Expensive’: Health Risk For Billions of People</title>
		<link>http://www.tapanray.in/innovative-medicines-too-damn-expensive-health-risk-for-billions-of-people/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=innovative-medicines-too-damn-expensive-health-risk-for-billions-of-people</link>
		<comments>http://www.tapanray.in/innovative-medicines-too-damn-expensive-health-risk-for-billions-of-people/#comments</comments>
		<pubDate>Mon, 18 Mar 2019 00:00:22 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[ailments]]></category>
		<category><![CDATA[arbitrary]]></category>
		<category><![CDATA[billions]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[damn]]></category>
		<category><![CDATA[disease]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[expensive]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovative]]></category>
		<category><![CDATA[life-saving]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[millions]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[risk]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[technology]]></category>
		<category><![CDATA[Too]]></category>
		<category><![CDATA[transparency]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9448</guid>
		<description><![CDATA[Most ‘medicines are too damn expensive. And a key part of the problem is the lack of consistent information about drug pricing. It’s not often that the Trump administration and the anti-poverty NGO Oxfam find themselves singing from the same &#8230; <a href="http://www.tapanray.in/innovative-medicines-too-damn-expensive-health-risk-for-billions-of-people/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/innovative-medicines-too-damn-expensive-health-risk-for-billions-of-people/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Protect Generic Drug Margin Moving Up The Value Chain</title>
		<link>http://www.tapanray.in/protect-generic-drug-margin-moving-up-the-value-chain/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=protect-generic-drug-margin-moving-up-the-value-chain</link>
		<comments>http://www.tapanray.in/protect-generic-drug-margin-moving-up-the-value-chain/#comments</comments>
		<pubDate>Mon, 03 Dec 2018 00:00:03 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[180-day]]></category>
		<category><![CDATA[ANDA]]></category>
		<category><![CDATA[commissioner]]></category>
		<category><![CDATA[commoditization]]></category>
		<category><![CDATA[commodity]]></category>
		<category><![CDATA[Complex]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[erosion]]></category>
		<category><![CDATA[Exclusivity]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[formulation]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovative]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9276</guid>
		<description><![CDATA[As an innovative drug molecule goes off-patent, it paves the way for market-entry of cheaper generic equivalents of the same. It benefits not just the patients, but all generic drug players awaiting this opportunity. But, in case of even those &#8230; <a href="http://www.tapanray.in/protect-generic-drug-margin-moving-up-the-value-chain/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/protect-generic-drug-margin-moving-up-the-value-chain/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
